What is the recommended management for intermittent claudication?

Management of Intermittent Claudication

All patients with intermittent claudication must begin with supervised exercise therapy (30–45 minutes per session, ≥3 times weekly for at least 12 weeks) combined with cilostazol 100 mg twice daily (if no heart failure) and optimal medical therapy before any revascularization is considered.

Immediate Cardiovascular Risk Reduction (Mandatory for All Patients)

• Start aspirin 75–325 mg daily or clopidogrel 75 mg daily as first-line antiplatelet therapy to reduce myocardial infarction, stroke, and vascular death. 1, 2
• Initiate high-intensity statin therapy regardless of baseline LDL cholesterol; this reduces cardiovascular events and improves walking distance. 2, 3
• Prescribe an ACE inhibitor or ARB for blood pressure control; these agents provide additional cardiovascular protection beyond blood pressure lowering in PAD. 2, 3
• Provide smoking cessation counseling at every visit with behavioral techniques plus pharmacologic aids (varenicline, bupropion, or nicotine replacement). 2, 3
• Do not add warfarin to antiplatelet therapy—it increases major bleeding without cardiovascular benefit. 1, 2

First-Line Therapy: Supervised Exercise Plus Cilostazol

Supervised Exercise (Class I, Level A)

• Enroll every patient in a supervised exercise program: 30–45 minutes per session, minimum 3 sessions per week, continued for at least 12 weeks. 1, 4, 2
• The exercise protocol is treadmill or track walking to near-maximal pain, followed by rest, then repeat the cycle throughout the session. 2, 3
• Supervised exercise improves maximal walking distance by 40–60% and is superior to unsupervised "just walk more" advice, which is ineffective. 1, 5
• When supervised programs are unavailable, structured home-based programs with behavioral change techniques are acceptable, but unstructured advice alone should be avoided. 2, 3

Cilostazol (Class I, Level A)

• Prescribe cilostazol 100 mg orally twice daily to all patients with lifestyle-limiting claudication who do not have heart failure; it improves walking distance by 40–60% after 12–24 weeks. 1, 2
• Cilostazol is absolutely contraindicated in any patient with heart failure because it is a phosphodiesterase type 3 inhibitor. 1, 2
• Pentoxifylline 400 mg three times daily is a second-line option only when cilostazol is contraindicated or not tolerated, but its benefit is marginal and not well established. 1, 2

Ineffective or Harmful Therapies to Avoid

• Do not prescribe L-arginine, propionyl-L-carnitine, ginkgo biloba, vitamin E, or oral vasodilator prostaglandins (beraprost, iloprost)—they lack proven efficacy. 1, 2
• Never use chelation therapy (EDTA)—it is harmful and contraindicated. 1, 2

When to Consider Revascularization

Revascularization is indicated only after ≥3 months of supervised exercise and optimal medical therapy have failed to adequately improve lifestyle-limiting disability. 1, 4, 2

Prerequisites for Revascularization

• The patient must have persistent severe lifestyle limitation or very short walking distance despite completing the exercise program. 1, 2, 6
• Lesion anatomy must suggest a favorable risk-benefit ratio (e.g., focal aortoiliac disease) with high likelihood of immediate and durable success. 1, 2, 6
• The patient should be a nonsmoker (or actively engaged in cessation), on optimal medical therapy, and have low physiologic and technical risk. 6, 7
• Do not perform revascularization in asymptomatic PAD or solely to prevent progression to critical limb ischemia—there is no benefit and potential harm. 2, 3, 6

Anatomic Approach to Revascularization

Aortoiliac Lesions

• Endovascular intervention is the preferred first-line strategy for TASC type A aortoiliac lesions (short, focal disease <5 cm). 1, 2, 3
• Primary stenting is effective for common iliac artery stenosis or occlusion; use provisional stenting for external iliac lesions when balloon angioplasty leaves >50% residual stenosis, flow-limiting dissection, or significant pressure gradient. 1, 2, 3
• Measure translesional pressure gradients (with and without vasodilation) for iliac stenoses of 50–75% diameter before deciding on intervention. 1, 2

Femoropopliteal Lesions

• Endovascular therapy is the first-choice for short femoropopliteal lesions (<25 cm), even in complex anatomy, particularly for high surgical risk patients. 2, 3, 8
• Use drug-eluting balloons or drug-eluting stents as the preferred devices for femoropopliteal disease; plain balloon angioplasty is inferior for lesions >5 cm. 2, 3, 8
• For long lesions (≥25 cm) in low surgical risk patients with available autologous great saphenous vein and life expectancy >2 years, open bypass with vein conduit provides superior long-term durability. 2, 3, 6
• Given the limited long-term durability of current endovascular technology, reserve femoropopliteal interventions for patients with severe lifestyle limitations and short walking distance. 6, 9

Common Femoral Artery Disease

• Open common femoral endarterectomy provides greater net benefit than endovascular intervention for common femoral artery disease in claudication. 6, 7
• The increase in endovascular treatment of common femoral artery disease post-2022 is inconsistent with appropriateness ratings and should be avoided. 7

Infrapopliteal Disease

• Do not perform isolated infrapopliteal revascularization for claudication alone—it is of unclear benefit and potentially harmful; reserve it for limb salvage in critical limb-threatening ischemia. 2, 3, 6
• The increase in infrapopliteal interventions for claudication post-2022 is inconsistent with appropriateness ratings. 7

Combined Therapy: Revascularization Plus Exercise

• Continue supervised exercise therapy after revascularization; combined therapy yields superior outcomes compared with either modality alone. 4, 2
• In the CLEVER trial, combined revascularization plus supervised exercise increased pain-free walking distance by 954 meters at 6 months versus 407 meters with exercise alone. 4

Advanced Antithrombotic Strategies Post-Revascularization

• Consider adding low-dose rivaroxaban 2.5 mg twice daily to aspirin 100 mg daily after revascularization in patients at high ischemic risk and low bleeding risk to further reduce cardiovascular and limb events. 2, 3, 8
• Dual antiplatelet therapy (aspirin plus clopidogrel) may be used after revascularization to reduce limb-related events, although cardiovascular benefit remains uncertain. 2, 3, 8
• Note that rivaroxaban trials excluded patients at high bleeding risk; carefully assess bleeding risk before initiating dual pathway inhibition. 8

Practical Treatment Algorithm

1. At diagnosis: Start aspirin or clopidogrel, high-intensity statin, ACE inhibitor or ARB, and intensive smoking cessation counseling. 2, 3
2. Immediately enroll in supervised exercise (30–45 min, ≥3×/week, minimum 12 weeks) and start cilostazol 100 mg twice daily (if no heart failure). 1, 2
3. Reassess at 12 weeks: If adequate functional improvement, continue exercise and medical therapy indefinitely. 2, 5
4. If persistent severe lifestyle limitation after 12 weeks: Obtain imaging to define anatomy and assess for revascularization candidacy. 1, 2, 6
5. For focal aortoiliac disease: Proceed with endovascular intervention (high success, low risk). 1, 2
6. For femoropopliteal disease: Endovascular therapy for short lesions (<25 cm) using drug-eluting technology; consider open bypass with vein for long lesions (≥25 cm) in low-risk patients. 2, 3, 8
7. After revascularization: Continue supervised exercise, maintain optimal medical therapy, and consider adding rivaroxaban 2.5 mg twice daily to aspirin if high ischemic risk and low bleeding risk. 4, 2, 8

Critical Pitfalls to Avoid

• Do not proceed to revascularization without completing ≥3 months of supervised exercise and optimal medical therapy—this violates Class I guideline recommendations. 1, 2, 6
• Do not withhold cilostazol from eligible patients without heart failure—it has Level A evidence for symptom improvement. 1, 2
• Do not perform endovascular intervention on common femoral artery disease; open endarterectomy is superior. 6, 7
• Do not revascularize isolated infrapopliteal disease for claudication—reserve it for limb salvage only. 2, 6, 7
• Do not use primary stenting in femoral, popliteal, or tibial arteries; reserve stenting for salvage after failed balloon angioplasty. 1, 3
• Do not recommend unstructured "just walk more" advice—it is ineffective and wastes the critical 12-week treatment window. 2, 3, 5

Real-World Evidence Supporting Exercise-First Approach

• In the Netherlands, implementation of exercise-first strategy increased from 63% in 2013 to 87% in 2017, resulting in fewer lower limb revascularizations and better survival compared with primary revascularization. 5
• Patients receiving primary supervised exercise had 90% freedom from intervention at 1 year and 82% at 2 years, even with predominantly outflow (femoropopliteal) disease. 5, 10
• A stepped care model (exercise first, then revascularization only if needed) saves €3.8–33 million annually in the Dutch healthcare system. 11